Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma (RCC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.6_suppl.683
Abstract: 683Background: Pazopanib, a highly lipophilic standard first-line therapy for metastatic RCC, is conventionally taken in a fasting state but has significant gastrointestinal toxicities and 96% of ingested drug is fecally excreted, with major financial implications.… read more here.
Keywords: low fat; fat meal; pazopanib low; meal palm ... See more keywords